

# Pfizer launches cancer bispecific Elranatamab in India

The therapy is approved to treat patients who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.



New Delhi: US pharma giant, Pfizer announced the commercial launch of its bispecific antibody, Elranatamab in India for the treatment of adult patients with relapsed or refractory

multiple myeloma —types of blood cancer.

The therapy is approved to treat patients who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Elranatamab is a fixed-dose subcutaneous injection, globally marketed under the brand name Elrexfio and was first approved by the US FDA in 2023.

It follows weekly administration, followed by every-other-week dosing for patients who respond after 24 weeks of weekly treatment.

The novel therapy is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager which destroys cancer cells by binding to both CD3, a protein found on the surface of T cells and BCMA, a protein found on the surface of B cells.

Under its Phase-3 pivotal study MagnetisMM-3, the drug demonstrated a median overall survival of 24.6 months, with a progression free survival of 17.2 months.

In India, the therapy will be marketed under the brand name Elduxio and is approved on condition of conducting a post-marketing surveillance study over at least 100 subjects.

Pfizer has not disclosed the drug's market price.

“The introduction of elranatamab in India marks another step forward in bringing a highly innovative, ready-to-use targeted therapy that combines strong clinical efficacy with the convenience of dosing for patients who are responding well to weekly therapy,” said Meenakshi Nevatia, Country President, Pfizer India.

Multiple myeloma, ranks as the second most common type of blood cancer globally and despite treatment advances, around 40 per cent of patients do not survive beyond five years.

**News Source:**

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/pfizer-launches-cancer-bispecific-elranatamab-in-india/131460145>